Onconova Therapeutics, Inc.
FORMULATION OF (E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYLSULPHO- NE WITH ENHANCED STABILITY AND BIOAVAILABILITY

Abstract:

Pharmaceutical compositions of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulpho- ne and pharmaceutically acceptable salts thereof are described as well as methods of their use, and a dose regimen of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulpho- ne, sodium salt to reduce the incidence of urothelial toxicity.